Search results for "Leukemia"

showing 10 items of 976 documents

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

2002

The feasibility of nonmyeloablative stem cell transplantation (NST) was evaluated in 22 adults with high-risk ALL. 16/22 patients had advanced disease and 11/22 had Ph+ ALL. Eleven patients received NST as first stem cell transplantation (SCT). Eleven patients had relapses after allogeneic or autologous SCT and underwent a salvage NST. 18/22 patients (82%) engrafted after NST. 13/16 patients (81%) with active disease reached complete remission (CR). 11 of 13 patients developed GVHD. After first NST 10/11 patients (91%) engrafted. Six of seven patients with active disease reached CR. Three of five relapsing patients reached subsequent CR after donor lymphocyte infusions, termination of immun…

AdultMaleRiskMelphalanCancer Researchmedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentSalvage therapyGraft vs Leukemia EffectPilot ProjectsAcute lymphocytic leukemiamedicineHumansPhiladelphia ChromosomeSurvival rateSalvage TherapyChemotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationImmunosuppressionHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryFludarabineSurvival RateTransplantationsurgical procedures operativeOncologyDisease ProgressionFeasibility StudiesFemalebusinessmedicine.drugLeukemia
researchProduct

Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group stu…

2005

Complete remission (CR) in patients with acute myeloid leukaemia (AML) is the primary endpoint for the evaluation of induction treatment and treatment strategies. However, the choice and application of the criteria for a haematological CR can often become a subject of debate because of regeneration more than 5% blasts may be present at the time of response evaluation; platelet and neutrophil recovery may be incomplete and marrow cellularity can vary. This study examined the individual parameters for CR in 1250 adult patients with de novo AML treated according to three successive study protocols. Patients with < or =5% blasts showed the best overall survival (OS) and the lowest relapse risk …

AdultMaleRiskmedicine.medical_specialtyPathologyAdolescentcomplete remissionMINIMAL RESIDUAL DISEASEDIAGNOSISGastroenterologyTHERAPYDisease-Free SurvivalAMLRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPlateletacute myeloid leukaemiaLymphocyte CountProportional Hazards ModelsrevisedHematologycriteriaProportional hazards modelbusiness.industryINDUCTIONRemission InductionCancerHematologyMiddle AgedCOLONY-STIMULATING FACTORmedicine.diseaseMinimal residual diseaseCANCERHIGH-DOSE CYTARABINELeukemiamedicine.anatomical_structureLeukemia MyeloidAcute DiseaseFemaleBone marrowbusinessBritish Journal of Haematology
researchProduct

Expanding the phenotype associated to KMT2A variants: overlapping clinical signs between Wiedemann–Steiner and Rubinstein–Taybi syndromes

2020

Lysine-specific methyltransferase 2A (KMT2A) is responsible for methylation of histone H3 (K4H3me) and contributes to chromatin remodeling, acting as “writer” of the epigenetic machinery. Mutations in KMT2A were first reported in Wiedemann–Steiner syndrome (WDSTS). More recently, KMT2A variants have been described in probands with a specific clinical diagnosis comprised in the so-called chromatinopathies. Such conditions, including WDSTS, are a group of overlapping disorders caused by mutations in genes coding for the epigenetic machinery. Among them, Rubinstein–Taybi syndrome (RSTS) is mainly caused by heterozygous pathogenic variants in CREBBP or EP300. In this work, we used next generati…

AdultMaleRubinstein-Taybi SyndromeAdolescentHistone-Lysine N-MethyltransferaseWiedemann–SteinerArticlePhenotypeSettore MED/03 - Genetica MedicaSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAKMT2A variantsMutationHumansFemaleEpigeneticsRubinstein–Taybi syndromesChildKMT2A Gene Wiedemann–Steiner syndrome Rubinstein–Taybi syndromeMyeloid-Lymphoid Leukemia Protein
researchProduct

Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplant…

2001

We investigated whether a T cell-reduced allogeneic stem cell transplant (SCT) with minimal conditioning and subsequent donor lymphocyte infusions (DLI) could reduce the incidence and severity of GVHD while retaining stable engraftment. Five patients with hematological malignancies (three MM, one CLL, one Chediak-Higashi syndrome) were conditioned with TBI (200 cGy). One patient additionally received fludarabine (120 mg/m(2)). CsA and mofetyl-mycophenolate (MMF) were administered to prevent GVHD. All patients were grafted with >3 x 10(6)/kg highly purified CD34(+) cells together with 2 x 10(6)/kg CD3(+) cells (three patients) or 1 x 10(5)/kg CD3(+) cells (two patients). Quick hematopoietic …

AdultMaleTime FactorsLymphocyte TransfusionT-LymphocytesT cellLymphocyteChronic lymphocytic leukemiamedicine.medical_treatmentHematopoietic stem cell transplantationLymphocyte DepletionFatal OutcomemedicineHumansTransplantation HomologousTreatment FailureTransplantation ChimeraTransplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedMycophenolic Acidmedicine.diseaseLeukemia Lymphocytic Chronic B-CellPeripheral stem cell transplantationFludarabineTransplantationmedicine.anatomical_structureHematologic NeoplasmsLymphocyte TransfusionImmunologyCyclosporineFemaleChediak-Higashi SyndromeMultiple MyelomabusinessImmunosuppressive AgentsVidarabineWhole-Body IrradiationFollow-Up Studiesmedicine.drugBone Marrow Transplantation
researchProduct

A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment

2011

Several chemokines/chemokine receptors such as CCR7, CXCR4 and CXCR5 attract chronic lymphocytic leukemia (CLL) cells to specific microenvironments. Here we have investigated whether the CX(3)CR1/CX(3)CL1 axis is involved in the interaction of CLL with their microenvironment. CLL cells from 52 patients expressed surface CX(3)CR1 and CX(3)CL1 and released constitutively soluble CX(3)CL1. One third of these were attracted in vitro by soluble CX(3)CL1. CX(3)CL1-induced phosphorylation of PI3K, Erk1/2, p38, Akt and Src was involved in induction of CLL chemotaxis. Leukemic B cells upregulated CXCR4 upon incubation with CX(3)CL1 and this was paralleled by increased chemotaxis to CXCL12. Akt phosp…

AdultMalechemokines; chronic lymphocytic leukemia (CLL); nurselike cells (NLCs); tumor microenvironmentCancer ResearchChemokineStromal cellChronic lymphocytic leukemiaCX3C Chemokine Receptor 1Antigens Differentiation MyelomonocyticchemokinesC-C chemokine receptor type 7Cell Communicationnurselike cells (NLCs)Chemokine receptorAntigens CDimmune system diseaseshemic and lymphatic diseaseschronic lymphocytic leukemia (CLL)medicineHumanstumor microenvironmentPhosphorylationAgedAged 80 and overTumor microenvironmentbiologyChemokine CX3CL1ChemistryChemotaxisHematologyMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-CellCX(3)CR1/CX(3)CL1 systemCX(3)CR1/CX(3)CL1 system; chronic lymphocytic leukemia.LeukemiaHaematopoiesisOncologychronic lymphocytic leukemia.Cancer researchbiology.proteinFemaleReceptors ChemokineLymph NodesProto-Oncogene Proteins c-aktSignal TransductionLeukemia
researchProduct

Immunophenotypical comparison of Gaucher's and pseudo-Gaucher cells.

1996

An immunohistochemical study on bone marrow biopsies and spleens of patients with Gaucher's disease and chronic myeloid leukemia was performed to investigate the immunophenotype of Gaucher's cells and pseudo-Gaucher cells. A panel of antibodies was used which were reactive on paraffin-embedded tissues and directed against different hematopoietic lineage cells. Gaucher's cells and pseudo-Gaucher cells expressed a very similar immunophenotype and displayed an intense reaction for the monocytic antibodies tested, thus confirming their common origin and that they belong to the same system. The expression of HLA-DR antigens was much stronger in Gaucher's than in pseudo-Gaucher cells. This last f…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyBone Marrow CellsBiologyPathology and Forensic MedicineImmunophenotypingNuclear FamilyImmunoenzyme TechniquesImmunophenotypingImmune systemAntigenAntigens CDLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansAgedPhagocytesGaucher Diseasenutritional and metabolic diseasesMyeloid leukemiaGeneral MedicineHLA-DR AntigensMiddle Agedmedicine.diseasenervous system diseasesLeukemiamedicine.anatomical_structureImmunologybiology.proteinImmunohistochemistryFemaleBone marrowAntibodySpleenPathology international
researchProduct

Investigation into mechanisms mediating the inhibitory effect of 1,4-benzodiazepines on mast cells by gene expression profiling.

2013

Abstract Aims This study aims to identify by a molecular genetic approach potential targets in mast cells at which 1,4-benzodiazepines may cause their inhibitory effect on mast cell activity. Main methods Gene expression analyses with microarray gene chip and/or quantitative PCR were performed using 1,4-benzodiazepine-treated human mast cell leukemia HMC-1.2 cells, promyelocytic leukemia HL-60 cells and human mast cells from healthy volunteers and patients with mast cell activation disease (MCAD). Pathway analysis was applied to search for enriched biological functions and canonical pathways within differentially regulated genes. Key findings Both neoplastic and normal human mast cells expr…

AdultMalegenetics [Mastocytosis]Gene ExpressionHL-60 CellsFlunitrazepamBiologyPolymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyClonazepamLYNddc:570medicineTranslocator proteinpharmacology [Flunitrazepam]HumansMast CellsGeneral Pharmacology Toxicology and Pharmaceuticsmethods [Polymerase Chain Reaction]Interleukin 5AgedRegulation of gene expressionBenzodiazepinonesGene Expression Profilingdrug effects [Gene Expression]General MedicineMiddle AgedMast cell leukemiamedicine.diseaseMast cellMicroarray Analysis4'-chlorodiazepamCell biologyInterleukin 33Gene expression profilingmedicine.anatomical_structuremethods [Microarray Analysis]biology.proteinpharmacology [Clonazepam]drug effects [Mast Cells]Femalepharmacology [Benzodiazepinones]Mastocytosismethods [Gene Expression Profiling]
researchProduct

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered ce…

2011

Disappearance of normal bone marrow (BM) plasma cells (PC) predicts malignant transformation of monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) into symptomatic multiple myeloma (MM). The homing, behavior and survival of normal PC, but also CD34 hematopoietic stem cells (HSC), B-cell precursors, and clonal PC largely depends on their interaction with stromal cell-derived factor-1 (SDF-1) expressing, potentially overlapping BM stromal cell niches. Here, we investigate the distribution, phenotypic characteristics and competitive migration capacity of these cell populations in patients with MGUS, SMM and MM vs healthy adults (HA) aged 60 years. Our result…

AdultMalemalignant transformationCancer ResearchPathologymedicine.medical_specialtyStromal cellPlasma CellsParaproteinemiasCD34Bone Marrow CellsEnzyme-Linked Immunosorbent AssayBiologyplasma cellsImmunophenotypingImmunophenotypingCell Movementhemic and lymphatic diseasesmedicineHumansProspective StudiesCells CulturedMultiple myelomaAgedAged 80 and overB-Lymphocytesmonoclonal gammopathiesbone marrow niche competitionHematologyMiddle AgedFlow CytometryHematopoietic Stem Cellsmedicine.diseaseClone CellsHaematopoiesisLeukemiamedicine.anatomical_structureOncologyCase-Control StudiesCancer researchFemaleBone marrowMultiple MyelomaMonoclonal gammopathy of undetermined significanceLeukemia
researchProduct

Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and h…

2000

Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter trial including 18 patients with refractory anemia with excess of blasts in transformation (RAEB-T), 86 patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndromes, and six patients with secondary AML after previous chemotherapy. Median age was 58 years (range: 18-76 years). Forty-nine patients (45%) achieved a complete remission (CR) after two induction cycles with idarubicin, ara-C, and etoposide, 52% of them aged/=60 years and 35% aged60 years (p=0.06). After two consolidation courses, patients were randomized to four cycles of either high-…

AdultMalemedicine.medical_specialtyAdolescentGastroenterologyInternal medicineMulticenter trialAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineIdarubicinProspective StudiesSurvival rateEtoposideAgedEtoposideDose-Response Relationship Drugbusiness.industryMyelodysplastic syndromesCytarabineHematologyGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival RateLeukemiaLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseCytarabineInterleukin-2FemaleImmunotherapyIdarubicinbusinessRefractory anemia with excess of blastsmedicine.drugAnnals of Hematology
researchProduct

Generic vancomycin products: Analysis of serum concentrations in patients with acute myeloid leukemia.

2013

Summary Concerns have recently emerged about the quality of generic vancomycin products. Our aim is to analyze serum vancomycin concentrations measured 48 hours after the start of an empirical treatment regimen in patients with acute myeloid leukemia (AML) who received one of the two generic vancomycin products available in France. Patients and methods Seventy-nine AML patients treated with vancomycin during two study periods were included in the study. Our vancomycin dosing regimen was based on the patients’ total body weight adjusted for renal clearance. Results A total of 93 serum vancomycin concentrations were collected: 31 in period 1 and 62 in period 2. In bivariate analysis, the mean…

AdultMalemedicine.medical_specialtyAdolescentPharmaceutical ScienceKidneyGastroenterologyYoung AdultVancomycinInternal medicinemedicineDrugs GenericHumansIn patientGeneric ProductAgedRetrospective StudiesPharmacologybusiness.industryMyeloid leukemiaSerum concentrationMiddle AgedAnti-Bacterial AgentsRegimenLeukemia Myeloid AcuteImmunologyVancomycinFemaleHemoglobinbusinessmedicine.drugClearanceAnnales pharmaceutiques francaises
researchProduct